2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2024 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.
Douglas A. Levine, MD, professor, Department of Obstetrics and Gynecology, director, Division of Gynecologic Oncology, NYU Langone Medical Center, discusses the recent strides made in the treatment of patients with cervical cancer.
The highlight of the progress in the treatment of this disease, says Levine, is in prevention, particularly with the HPV vaccine. He expects that we will see a dramatic decrease in cervical cancer diagnoses as more and more people continue to receive the HPV vaccine.
As for therapeutic advancements, Levine discusses effective treatments involving angiogenic inhibitors as well as the more novel PARP inhibitors.
While cervical cancer screening continues to be highly effective and helpful for patients, ovarian cancer screening still needs further development, says Levine. Overall, though, the treatment landscape is quickly changing, and Levine believes experts in this field are succeeding in helping their patients and advancing their mission.
Related Content: